Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**

Archives of Hepatitis Research
Review Article
Abstract 
Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated interferon and ribavirin (PR) is only recommended to patients with tolerance to interferon (IFN). IFN-free treatments are now considered elective drugs for patients with chronic HCV. More than 90% of patients infected with HCV genotype 1 or 4 (fewer with other genotypes) show sustained virological response, when treated with sofosbuvir combined with simeprevir, daclatasvir or ledipasvir, or by the combination of paritaprevir with ritonavir, ombitasvir and dasabuvir, with or without ribavirin.

http://www.peertechz.com/Hepatitis-Research/pdf/AHR-1-103.pdf

Comments

Popular posts from this blog

Successful treatment of Budd- Chiari Syndrome with Percutaneous transluminal Balloon Angioplasty

Case Report: Reynolds Syndrome

Ministernotomy Thymectomy in Mysthania Gravis-Future